

## ORIGINAL ARTICLE

# Prevalence of Multidrug-Resistant Organisms in Hospitalized Pediatric Refugees in an University Children's Hospital in Germany 2015–2016

Tobias Tenenbaum, MD;<sup>1</sup> Klaus-Peter Becker, MD;<sup>2</sup> Bettina Lange, MD;<sup>2,3</sup> Anka Martin, MD;<sup>4</sup> Peter Schäfer, MD;<sup>5</sup> Stefan Weichert, MD;<sup>1</sup> Horst Schrotten, MD<sup>1</sup>

**OBJECTIVE.** To determine the prevalence of multidrug-resistant organisms (MDROs) colonizing in pediatric refugees admitted to a University Children Hospital in Germany.

**DESIGN.** Retrospective observational study.

**SETTING.** General pediatric and pediatric surgery units.

**PATIENTS.** In Germany, recommendations for MDRO screening of pediatric refugees were recently published. According to these and institutional recommendations, all hospitalized pediatric refugees were screened for MDROs between October 2015 and March 2016.

**METHODS.** Using electronic surveillance data, we performed a chart review to identify the prevalence of MDROs among and the clinical diagnoses of pediatric refugees.

**RESULTS.** Among 325 patients hospitalized for various causes, most frequently gastroenteritis (30.9%), MDROs were detected in 33.8%. Most of these patients were colonized with multidrug-resistant Gram-negative (MRGN) bacteria (113 isolates), mostly 2MRGN/ESBL (87 isolates); some patients were colonized with methicillin-resistant *Staphylococcus aureus* (MRSA, 22 isolates); and 1 patient was colonized with vancomycin-resistant enterococci (VRE). Among 110 refugee patients, we detected single colonization with an MDRO in 84 patients (76.4%), co-colonization with 2 pathogens in 23 patients (20.9%), and triple colonization in 3 patients (2.7%). However, infections with MDROs occurred in only 3.6% of pediatric refugees. The peak of positive MDRO screening results in 2015 correlated with an increased hospitalization rate.

**CONCLUSION.** Implementation of infection control measures among pediatric refugees is challenging. Due to the high frequency of MDROs in these patients, current screening, isolation, and treatment strategies may have to be adapted.

*Infect Control Hosp Epidemiol* 2016;37:1310–1314

Due to war, political persecution, and national instability, increasing numbers of refugees from the Near and Middle East, Africa, and the Balkans have sought for asylum in many European countries, especially Germany. In 2015, Germany experienced the largest asylum surge and arrival of refugees since World War II. The number of registered asylum seekers reached nearly half a million, most coming from Syria, but almost as many remain unregistered. Approximately 25% of asylum seekers are children.<sup>1</sup> As a result of the withdrawal of American troops stationed in the Rhein-Neckar area in previous years, the city of Mannheim/Baden-Württemberg was able to provide one of the largest hosting facilities for refugees in Germany. Thus, increased visit and admission rates of refugees for various causes accrued.

Early and sufficient medical care for refugees is essential. Especially among children, who frequently suffer from infectious diseases, antibiotic therapy is frequently prescribed, but it may be less effective if the illness is caused by antibiotic-resistant organisms.<sup>2</sup> Treatment of infections caused by multidrug-resistant organisms (MDROs) is even more difficult in children because antibiotic treatment options are limited. Colonization with an MDRO has also been described among international travelers returning to Germany.<sup>3,4</sup> In Syrian war-injured patients, MDROs have also been isolated frequently.<sup>5</sup> Therefore, prevention strategies to avoid colonization and subsequent infection are warranted.

Affiliations: 1. Pediatric Infectious Diseases, University Children's Hospital Mannheim, Heidelberg University, Mannheim, Germany; 2. Administrative Department of Hygiene, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; 3. Department of Pediatric Surgery, University Children's Hospital Mannheim, Heidelberg University, Mannheim, Germany; 4. Institute for Medical Microbiology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; 5. Public Health Department Mannheim, Mannheim, Germany.

Received April 21, 2016; accepted July 7, 2016; electronically published August 15, 2016

© 2016 by The Society for Healthcare Epidemiology of America. All rights reserved. 0899-823X/2016/3711-0006. DOI: 10.1017/ice.2016.179

International uniform recommendations for MDRO screening in hospitalized patients from MDRO endemic countries do not exist. In Germany, the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute (RKI), the German Society of Pediatric Infectious Diseases (DGPI), the Society of Tropical Pediatrics and International Child Health, and the Professional Association of Pediatrics recently published recommendations for refugee screening.<sup>6,7</sup> Here, we report a high frequency of MDROs among pediatric refugees hospitalized at the University Children's Hospital in Mannheim, Germany.

## METHODS

### Study Population

In this retrospective analysis, we reviewed laboratory screening results of all pediatric refugees seen at our hospital from October 2015 to March 2016 that were hospitalized in the Department of Pediatrics and the Department of Pediatric Surgery at the University Hospital Mannheim for various causes. Resident neonatal and pediatric patients with MDROs were excluded from the analysis. Routine screening procedures were conducted in accordance with recently published screening recommendations and already implemented institutional guidelines.<sup>6,7</sup> Children were screened for multidrug-resistant Gram-negative (MRGN) bacteria (all patients) and VRE (oncologic patients only) via rectal swab and for MRSA (all patients) via nasopharyngeal swab. Most of the refugees were directly placed on contact precautions during the hospital stay. If the patient could not initially be isolated (due to lack of room capacity) and an MDRO was found after admission, contact precautions were initiated subsequently. The main demographic features as well as data related to the reason for admission were collected retrospectively by chart review.

### Microbiological Investigation

According to the phenotypic definition of the KRINKO recommendation, *Enterobacteriaceae* detected by rectal swab were classified as 2MRGN/ESBL, 3MRGN, or 4MRGN.<sup>8,9</sup> Gram-negative bacteria resistant against 2, 3, or 4 antibiotic groups (penicillins with piperacillin as surrogate substance, cephalosporins with cefotaxime and/or ceftazidime as surrogate substance, and fluoroquinolones with ciprofloxacin as surrogate substance) were characterized as 3MRGN, while bacteria characterized as 4MRGN had additional resistance against carbapenems, with imipenem and/or meropenem as surrogate substance. In children, fluoroquinolones cannot be applied routinely, thus, the 2MRGN antibiotic group was implemented especially for neonates.

Rectal swabs were cultivated for MRGN on selective media: CHROMAgar ESBL, (MAST Diagnostica, Merseyside, UK) and Ceftrimid-Agar (bioMérieux, Marcy-l'Étoile, France). For identification and susceptibility testing of resistant colonies, VITEK 2 (bioMérieux) with Clinical and Laboratory Standards Institute (CLSI) interpretative standards were used. Decreased carbapenem susceptibility in *Enterobacteriaceae* was confirmed

using molecular methods at the National Reference Center for Gram-negative bacteria. Nasopharyngeal swabs for MRSA detection were plated on ChromID MRSA Agar (bioMérieux). Rectal swabs for VRE detections were plated on VRE Select Agar (BioRad, Berkeley, CA, USA).

## RESULTS

In the course of 2015, an increasing number of refugees were accommodated in different refugee camps in Mannheim, Germany. Most of the refugees in the second half of 2015 came from Syria (40.2%), Afghanistan (16.1%), Iraq (13.5%), the Gambia (7.3%), Albania (4.3%), Iran (2.7%), Nigeria (2.7%) and from 19 other countries (13.2%). In the same time period, 28.1% of the refugees registered during an initial health investigation were children and adolescents (0–3 years, 5.6%; 4–6 years, 4.2%; 7–10 years, 5.2%; 11–15 years, 5% and 16–18 years, 8.1%).

We analyzed all pediatric refugees admitted to the Department of Pediatrics and the Department of Pediatric Surgery with respect to MDRO colonization. In total, 325 children were hospitalized; of these, 110 (33.8%) had a positive MDRO screening result. The numbers of hospitalized patients with a positive MDRO screening result were similar in both pediatric departments in 2015 and 2016. In the Department of Pediatrics, 66 of 179 hospitalized children (36.8%) were positive for an MDRO in 2015 and 27 of 77 hospitalized children (35.1%) were positive for an MDRO in 2016. In the Department of Pediatric Surgery, 11 of 40 (27.5%) were positive for an MDRO in 2015 and 6 of 29 (20.7%) patients were positive for an MDRO in 2016. However, the majority of patients were seen in pediatric emergency (881 patients) and on an outpatient basis (122 patients) without the necessity of admission. Among the 110 hospitalized children, 62 (56.4%) were male and 48 (43.6%) were female; the median age was 21 months (range, 1–202 months). The country distribution of hospitalized children reflected the general country distribution of all refugees in Mannheim; these children were refugees from Syria (51.8%), Afghanistan (22.9%), Irak (21.7%), Iran (1.2%), Bosnia (1.2%), and Nigeria (1.2%).

Between October 2015 and March 2016, the MDRO screening results of pediatric refugees in the Departments of Pediatrics and Pediatric Surgery revealed a peak of positive results in November and December 2015, which correlated with the high number of refugees in Mannheim during that time period (Figure. 1). The number of isolates decreased over the course of 2016, also corresponding to the decreasing hospitalized refugee numbers and total number of refugees in Mannheim. The rates of MDRO-colonized patients at our institution were similar between October 2015 and February 2016: October 2015, 0.29%; November 2015, 0.24%; December 2015, 0.26%; January 2016, 0.20%; February 2016, 0.24%. Only in March did we observe an unexplained decrease (0.08%) in the colonization rate.

The majority of patients were colonized with MRGN bacteria (113 isolates), mostly 2MRGN/ESBL (87 isolates), and in a minority were colonized with MRSA (22 isolates), and

1 patient was colonized with VRE (Table 1). If a patient was readmitted to the hospital in 2015 or 2016, each isolate was counted only once. *Escherichia coli* 3MRGN was detected in 22 of 136 (16.2%) of the isolates; *E. coli* 4MRGN was detected in 2 of 136 (1.5%) of the isolates; and *Klebsiella pneumoniae* 3MRGN was detected in 2 of 136 (1.5%) of the isolates. Among 110 refugee patients, we detected single colonization with an MDRO in 84 patients (76.4%), co-colonization with 2 pathogens in 23 patients (20.9%), and triple colonization in 3 patients (2.7%). No MDRO isolates of *Pseudomonas aeruginosa*, *Acinetobacter baumannii* complex, *Citrobacter freundii*, *Enterobacter cloacae*, *Serratia marcescens*, or *Morganella morganii* were detected among hospitalized pediatric refugees.

The majority of the hospitalized pediatric patients were admitted for infectious diseases such as gastroenteritis (33.9%), pneumonia (12.7%), bronchiolitis (8.1%), influenza

(4.5%), and skin and soft-tissue infections (6.3%) (Table 2). In 3 patients colonized with MRSA, the pathogen was also the cause of skin and soft-tissue infection, and in 1 patient an *E. coli* 3MRGN was the cause of a pyelonephritis. Therefore, infections with MDRO in pediatric refugees were infrequently observed and occurred in only 3.6% of patients. All other patients were only colonized with an MDRO. Other children were hospitalized for neurological disorders (4.5%), hematologic/oncologic disorders (6.4%), surgery or due to trauma (9.1%), and other causes (1.8%).

DISCUSSION

In this retrospective analysis of screened pediatric refugees, a large proportion of children (33.8%) were colonized with an MDRO. The most frequently detected pathogens were 2MRGN *E. coli*, followed by 3MRGN *E. coli*, MRSA, 2MRGN *K. pneumoniae*, 3MRGN *K. pneumoniae*, 4MRGN *E. coli*, and VRE. Only 4 infections caused by an MDRO were observed in screened pediatric refugees.

Screening for MRGN in non-neonates is generally not established. In neonates, it has already been demonstrated that surveillance can contribute in predicting Gram-negative and MRGN sepsis.<sup>10,11</sup> In contrast, recent data in adults suggest that contact precautions even over 5 years may not lead to a lower MRGN incidence in a hospital setting.<sup>12</sup> MRSA screening for risk groups has been established for many years in Germany.<sup>13</sup> Still, data are conflicting regarding whether MRSA screening effectively can prevent or stop outbreaks or hinder further spread of this pathogen.<sup>14-16</sup>

Two recent publications have described the prevalence of MDROs among refugees. In a study by Reinheimer et al<sup>17</sup> of 143 adult refugees and a study by Heudorf et al<sup>18</sup> of




FIGURE 1. Number of refugees (adults and children) located in refugee camps in Mannheim, Germany, between January 2015 and March 2016.

TABLE 1. MDRO Screening Results of Pediatric Refugees in the Departments of Pediatrics and Pediatric Surgery Between October 2015 and March 2016

MDRO	2015			2016			Total	%
	October	November	December	January	February	March		
<i>Escherichia coli</i> (2MRGN/ESBL)	17	16	19	8	7	1	68	50.0
<i>E. coli</i> (3MRGN)	5	6	1	5	4	1	22	16.2
<i>E. coli</i> (4MRGN)		2					2	1.5
<i>Klebsiella pneumoniae</i> (2MRGN/ESBL)	1	3	5	3	6		18	13.2
<i>K. pneumoniae</i> (3MRGN)	1	1					2	1.5
<i>K. pneumoniae</i> (4MRGN)							0	0
<i>K. oxytoca</i> (2MRGN/ESBL)						1	1	0.7
<i>K. oxytoca</i> (3MRGN)							0	0
<i>K. oxytoca</i> (4MRGN)							0	0
<i>Staphylococcus aureus</i> (MRSA)	4	5	6	4	2	1	22	16.2
<i>Enterococcus faecium</i> (VRE)			1				1	0.7
Total	28	33	31	20	19	4	136 <sup>a</sup>	100

NOTE. MDRO, multiple-drug-resistant organism; ESBL, extended-spectrum β-lactamase; MRGN, multiple-drug-resistant Gram-negative, MRSA, methicillin-resistant *Staphylococcus aureus*; VRE, vancomycin-resistant enterococci.

<sup>a</sup>Among 110 refugee patients, we detected single colonization with an MDRO in 84 patients (76.4%), co-colonization with 2 pathogens in 23 patients (20.9%), and triple colonization in 3 patients (2.7%).

TABLE 2. Causes of Hospitalization of Pediatric Refugees in the Department of Pediatrics and Pediatric Surgery Between October 2015 and March 2016

Cause of Hospitalization	2015	2016	Total	%
<b>Infections</b>				
Gastroenteritis	32	2	34	30.9
Pneumonia	5	9	14	12.7
Bronchiolitis	5	4	9	8.2
Influenza	1	4	5	4.5
Skin and soft-tissue infection <sup>a</sup>	2	5	7	6.4
Sepsis	2	0	2	1.8
Viral infection	2	0	2	1.8
Pyelonephritis <sup>a</sup>	1	2	3	2.7
Herpes stomatitis	2	0	2	1.8
Orbital cellulitis	1	0	1	0.9
Tuberculosis	1	0	1	0.9
Osteomyelitis	1	0	1	0.9
Otitis media	0	1	1	0.9
Head lice	0	1	1	0.9
Conjunctivitis	0	1	1	0.9
Exanthema	0	1	1	0.9
Varicella	0	1	1	0.9
Total infections	55	31	86	78.2
Total non-infectious causes <sup>b</sup>	13	11	24	21.8
Total sum	68	42	110	100.0

<sup>a</sup>In 3 patients colonized with MRSA, the pathogen was also the cause of a skin and soft-tissue infection, and in 1 patient an *E. coli* 3MRGN was cause of a pyelonephritis.

<sup>b</sup>Non-infectious causes for hospitalization included neurological disorders (5 cases; 4.5%), hematologic/oncologic disorders (7 cases; 6.4%), surgery/trauma patients (10 cases; 9.1%) and other causes (2 cases; 1.8%).

119 unaccompanied refugee minors, colonization with MRGN bacteria was more frequent than in the general German population. An antibiotic-resistance surveillance study performed between 2009 and 2012 in Germany showed a MRSA prevalence of ~3.3% among outpatients and 3.4% among hospitalized patients, a MRGN *E. coli* prevalence of ~5.4% among outpatients and 6.9% among hospitalized patients, and a MRGN *K. pneumonia* prevalence of 2.1% among pediatric outpatients and 9.0% among hospitalized children.<sup>19</sup> Most of the pediatric patients in the study by Heudorf et al. were from Afghanistan, whereas in our study most of the children came from Syria. Like our study, more individuals were colonized with 2MRGN than with 3MRGN. In our analysis, 4MRGN colonization was detected in 2 children.

The rise of Carbapenemase-producing *Enterobacteriaceae* in Europe is a serious concern in this context.<sup>20</sup> A Swiss study performed at the University Hospital Zurich detected a prevalence of 13.9% 2MRGN bacterial colonization and 7.9% 3MRGN bacterial colonization among travelers hospitalized abroad.<sup>21</sup> In an Italian sentinel surveillance study analyzing data from 48 Syrian asylum seekers with a median age of 20 years (23% children), 3 of 48 refugees (6.3%) carried MRSA and 11 of

48 (22.9%) carried MRGN.<sup>22</sup> Interestingly, in 4 of 48 refugees (8.3%), *Pseudomonas* strains (non-*P. aeruginosa*) were meropenem resistant. The relevance of this finding for high-risk groups with chronic lung diseases is currently under debate.

Herein, we have described the largest screened cohort of pediatric refugees to date with a high frequency of MDROs. The limitations of our study include the lack of an age-matched control group, but this was not possible due to the retrospective design of the study and the absence of universal MDRO screening. The sensitivity of detecting MRSA could also have been improved by using not only nasopharyngeal swabs but also swabs of additional sites (eg, rectum, axilla). Moreover, detailed refugee itineraries were not completely available due to lack of previous medical patient records and language barriers. Additionally, we can only speculate whether the children acquired their MDRO colonization during their travel or in their home country. Because most of the pediatric refugees were hospitalized in Mannheim for the first time and had not been in any other German hospital, it is unlikely that they acquired the MDRO at our hospital. Moreover, MDRO screening was performed directly after first contact in the emergency department, which makes an acquisition and consecutive colonization in the hospital before that time point also very unlikely. The sense and non-sense of screening for MDROs is under intense scrutiny.<sup>23,24</sup> Obviously, screening and pre-emptive isolation of risk groups can prevent nosocomial colonization and subsequent infection. Because the antibiotic armamentarium for MDROs is generally limited, the prevention of MDRO transmission is desirable. Increased costs of infection control measures and limited isolation capacities in hospitals have to be weighed against potential stigmatization and poorer patient care. Moreover, decolonization strategies for MRSA in refugees may not work well due to suboptimal conditions in camps, overcrowding, and language barriers to understanding medical indications. Therefore, we argue for a critical debate on MDROs, especially MRGN screening and isolation policies, not only for pediatric refugees but also for residential children.

#### ACKNOWLEDGMENTS

*Potential conflicts of interest:* All authors report no conflicts of interest relevant to this article.

*Financial support:* No financial support for this study was received.

Address correspondence to Tobias Tenenbaum, MD, Pediatric Infectious Diseases, University Children's Hospital Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany (Tobias.Tenenbaum@umm.de).

#### REFERENCES

1. Flüchtlinge BfMu. Updated asylum data. Federal Office for Migration and Refugees [in German] website. [http://www.bamf.de/SharedDocs/Anlagen/DE/Downloads/Infothek/Statistik/Asyl/statistik-anlage-teil-4-aktuelle-zahlen-zu-asyl.pdf?\\_\\_blob=publicationFile](http://www.bamf.de/SharedDocs/Anlagen/DE/Downloads/Infothek/Statistik/Asyl/statistik-anlage-teil-4-aktuelle-zahlen-zu-asyl.pdf?__blob=publicationFile). Published 2016. Accessed March 4, 2016.

2. Logan LK. Carbapenem-resistant enterobacteriaceae: an emerging problem in children. *Clin Infect Dis* 2012;55:852–859.
3. Hassing RJ, Alsmä J, Arcilla MS, van Genderen PJ, Stricker BH, Verbon A. International travel and acquisition of multidrug-resistant enterobacteriaceae: a systematic review. *Euro Surveill* 2015;20.
4. Lubbert C, Straube L, Stein C, et al. Colonization with extended-spectrum beta-lactamase-producing and carbapenemase-producing enterobacteriaceae in international travelers returning to Germany. *Int J Med Microbiol* 2015;305:148–156.
5. Teicher CL, Ronat JB, Fakhri RM, et al. Antimicrobial drug-resistant bacteria isolated from Syrian war-injured patients, August 2011–March 2013. *Emerg Infect Dis* 2014;20:1949–1951.
6. Stellungnahme des Robert Koch-Instituts zu Frage des Screenings von Asylsuchenden auf Multiresistente Erreger (MRE). [Statement of the Robert Koch Institute regarding screening of asylum seekers for multidrug resistant bacteria.] Robert Koch Institute (RKI) website. [https://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GesundAZ/Content/A/Asylsuchende/Inhalt/MRE-Screening\\_Asylsuchende.pdf?\\_\\_blob=publicationFile](https://www.rki.de/DE/Content/Gesundheitsmonitoring/Gesundheitsberichterstattung/GesundAZ/Content/A/Asylsuchende/Inhalt/MRE-Screening_Asylsuchende.pdf?__blob=publicationFile). Published 2016. Accessed March 4, 2016.
7. Pfeil J, Kobbe R, Trapp S, Kitz C, Hufnagel M. Recommendations for the diagnosis and prevention of infectious diseases in pediatric and adolescent refugees in Germany. Statement of the German Society of Pediatric Infectious Diseases, the Society of Tropical Pediatrics and International Child Health, and the Professional Association of Pediatricians [in German]. *Monatsschrift Kinderheilkd* 2015;163:1269–1285.
8. Commission recommendation for hospital hygiene and infection prevention (KRINKO) at the Robert Koch Institute (RKI). Hygiene measures for infection or colonization with multidrug-resistant Gram-negative bacilli. Commission recommendation for hospital hygiene and infection prevention (KRINKO) at the Robert Koch Institute (RKI) [in German]. *Bundesgesundheitsbl* 2012;55:1311–1354.
9. Commission recommendation for hospital hygiene and infection prevention (KRINKO) at the Robert Koch Institute (RKI). Praktische Umsetzung sowie krankenhaushygienische und infektionspräventive Konsequenzen des mikrobiellen Kolonisationscreenings bei intensivmedizinisch behandelten Früh- und Neugeborenen. Ergänzende Empfehlung der KRINKO beim Robert Koch-Institut, Berlin, zur Implementierung der Empfehlungen zur Prävention nosokomialer Infektionen bei neonatologischen Intensivpflegepatienten mit einem Geburtsgewicht unter 1.500 g aus dem Jahr 2007 und 2012. *Epidem Bull* 2013;421–433.
10. Parm U, Metsvaht T, Sepp E, et al. Mucosal surveillance cultures in predicting Gram-negative late-onset sepsis in neonatal intensive care units. *J Hosp Infect* 2011;78:327–332.
11. Mammina C, Di Carlo P, Cipolla D, et al. Surveillance of multidrug-resistant Gram-negative bacilli in a neonatal intensive care unit: prominent role of cross transmission. *Am J Infect Control* 2007;35:222–230.
12. Zahar JR, Poirel L, Dupont C, Fortineau N, Nassif X, Nordmann P. About the usefulness of contact precautions for carriers of extended-spectrum beta-lactamase-producing *Escherichia coli*. *BMC Infect Dis* 2015;15:512.
13. Commission recommendation for hospital hygiene and infection prevention (KRINKO) at the Robert Koch Institute (RKI). Recommendations for prevention and control of methicillin-resistant staphylococcus aureus (MRSA) in medical and nursing facilities [in German]. *Bundesgesundheitsbl* 2014;57:696–732.
14. Gidengil CA, Gay C, Huang SS, Platt R, Yokoe D, Lee GM. Cost-effectiveness of strategies to prevent methicillin-resistant *Staphylococcus aureus* transmission and infection in an intensive care unit. *Infect Control Hosp Epidemiol* 2015;36:17–27.
15. Baud O, Giron S, Aumeran C, et al. First outbreak of community-acquired MRSA USA300 in France: failure to suppress prolonged MRSA carriage despite decontamination procedures. *Eur J Clin Microbiol Infect Dis* 2014;33:1757–1762.
16. Patel M, Thomas HC, Room J, Wilson Y, Kearns A, Gray J. Successful control of nosocomial transmission of the USA300 clone of community-acquired methicillin-resistant *Staphylococcus aureus* in a UK paediatric burn centre. *J Hosp Infect* 2013;84:319–322.
17. Reinheimer C, Kempf VA, Gottig S, et al. Multidrug-resistant organisms detected in refugee patients admitted to a university hospital, Germany, June–December 2015. *Euro Surveill* 2016;21.
18. Heudorf U, Krackhardt B, Karathana M, Kleinkauf N, Zinn C. Multidrug-resistant bacteria in unaccompanied refugee minors arriving in Frankfurt AM Main, Germany, October to November 2015. *Euro Surveill* 2016;21. DOI: 10.2807/1560-7917.ES.2016.21.2.30109.
19. Eckmanns T, Richter D, Feig M. MRSA and ESBL in outpatient: development from 2008 up to 2012 and socio-demographic differences [in German]. *Berl Munch Tierarztl Wochenschr* 2014;127:399–402.
20. Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL, European Survey of Carbapenemase-Producing Enterobacteriaceae Working Group. Carbapenemase-producing enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. *Euro Surveill* 2015;20. DOI: 10.2807/1560-7917.ES.2015.20.45.30062.
21. Nemeth J, Ledergerber B, Preiswerk B, et al. Multidrug-resistant bacteria in travellers hospitalized abroad: prevalence, characteristics, and influence on clinical outcome. *J Hosp Infect* 2012;82:254–259.
22. Angeletti S, Ceccarelli G, Vita S, et al. Unusual microorganisms and antimicrobial resistances in a group of Syrian migrants: sentinel surveillance data from an asylum seekers centre in Italy. *Travel Med Infect Dis* 2016;14:115–122.
23. Kaspar T, Schweiger A, Droz S, Marschall J. Colonization with resistant microorganisms in patients transferred from abroad: who needs to be screened? *Antimicrob Resist Infect Control* 2015;4:31. DOI: 10.1186/s13756-015-0071-6.
24. Seybold U, Wagener J, Jung J, Sammet S. Multidrug-resistant organisms among refugees in Germany: we need evidence-based care, not fear-based screening. *J Hosp Infect* 2016;92:229–231.